Pure Global
NCT00198172

Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors

Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
Indiana University School of Medicine·Phase 2·ClinicalTrials.gov·drugTerminated
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Germ Cell Tumor
Drug/Device/Intervention
Cisplatin plus Epirubicin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Indiana University School of Medicine
Funder
Indiana University
Location
Indianapolis, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Oct 01, 2000
End date
Mar 01, 2007
Enrollment
37 participants
Primary outcome

To determine the feasibility and toxicity of combining epirubicin to fixed dose cisplatin

Summary

This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with
 refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage
 chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study
 E39897.

ICD-10 classifications
Malignant neoplasmsMalignant neoplasm: JejunumMalignant neoplasm: PrepuceMalignant neoplasm: Female genital organ, unspecifiedMalignant neoplasm: Vulva, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00198172
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00198172 through Pure Global AI's free database. This Phase 2 trial is sponsored by Indiana University School of Medicine and is currently Terminated. The study focuses on Germ Cell Tumor. Target enrollment is 37 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.